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Cancer and cancer therapy-related cognitive impairment (formerly known as chemobrain
or chemo-fog) are often described in the literature. In the past, studies have failed to
prove the existence of cancer therapy-related cognitive dysfunction. However, more
recently, prospective trials have shown that patients undergoing chemotherapy do display
impairment in speciﬁc cognitive domains. Aging confers an increased risk of developing
cancer, as well as cognitive impairment. The Geriatric Oncology clinic of the Segal
Cancer Centre, Jewish General Hospital in Montreal was founded in 2006 to address the
unique needs of older cancer patients. We will describe two cases of cancer therapy-
related cognitive impairment from our Geriatric Oncology clinic. The ﬁrst case is that
of a 75 year old male diagnosed with stage III non-small cell lung carcinoma who
complained of forgetfulness since starting carboplatin-paclitaxel. The second case is that
of a 65 year old female diagnosed with stage I, estrogen-receptor-positive breast cancer
who had undergone lumpectomy followed by adjuvant cyclophosphamide, methotrexate
and ﬂuorouracil chemotherapy, radiation therapy and was on exemestane when she was
evaluated. We will also brieﬂy review the literature of cancer therapy-related cognitive
impairment.
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INTRODUCTION
Cancer treatment is a ﬁeld that has made great advances in the
last century. Survival has been greatly affected by novel thera-
pies. However, with increased long-term survival from cancer,
the long-term effects of treatment remain to be seen. The notion
of the effects of chemotherapy on cognition, although initially
described in the 1970s, only began to garner attention in the
late 1990s as it became increasingly recognized as a common and
signiﬁcant symptom in cancer survivors (Hede, 2008). Aging is
not only the most important risk factor for developing cancer
but also a major predisposing factor to cognitive dysfunction.
Forty-three percent of new cancer cases occur in those aged
70 and above, and 60% of cancer deaths occur in this age
group (Canadian Cancer Society’s Steering Committee on Can-
cer Statistics, 2012). Similarly, the number of Canadians living
with cognitive impairment, including dementia, now stands at
747,000 and will double to 1.4 million by 2031 (Alzheimer Soci-
ety of Canada: “A new way of looking at the impact of dementia
in Canada”, September 2012). Older cancer patients with pre-
existing cognitive impairment are at greater risk of worsening
cognitive dysfunction during cancer treatments, which can subse-
quently lead to functional decline and loss of autonomy (Smith
et al., 2009). The added insult that chemotherapy may incur
can impact these patients to a greater extent than their younger
counterparts. Cognitively impaired individuals may also not have
the capacity to fully comprehend their cancer diagnosis and
proposed treatments, thus rendering informed decision-making
challenging.
Researchers are now aiming to study cognitive impairment due
to cancer treatment more systematically in the elderly. Hurria
et al. (2006) were among the ﬁrst to investigate cognitive decline
in patients over the age of 65 receiving chemotherapy. Thirty-
one patients with breast cancer receiving adjuvant chemotherapy
underwent neuropsychological testing prior to and after treat-
ment. It was observed that 39% of patients experienced a decline
in cognitive domains including visual memory, spatial function,
psychomotor function, and attention. The team of (Kvale et al.,
2010) also attempted to show the effect of cancer treatment in
the geriatric population. Their study used data from a previous
trial (ACTIVE trial) looking at the effect of cognitive training
on 2,802 individuals aged 65–94 years. They identiﬁed subjects
who developed cancer during their enrolment in the study who
had a baseline assessment at least 2 years prior to their diagnosis.
Thirty-seven of these patients had a cancer diagnosis and were
assessed after treatment and followed with annual assessments.
They were compared to age-matched control groups without a
cancer diagnosis. A trend toward cognitive decline was found
after treatment for cancer although it was not statistically sig-
niﬁcant (p = 0.07). Poor baseline cognitive functioning, older
age and increased number of depressive symptoms were predic-
tive of poorer post-therapy cognitive test scoring (p = 0.047).
Another study by Minisini et al. (2008) prospectively looked at a
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group of 61 patients with a diagnosis of cancer. These patients
were divided into three groups: those who did not receive can-
cer treatment, those who received chemotherapy, and those who
received hormonal therapy. Cognitive assessmentswere conducted
at the ﬁrst visit and at three follow-up visits for a duration of
6 months. The mean ages were 71, 71.5, and 72 years old in
the group without cancer treatment, with chemotherapy, and on
hormonal therapy, respectively. Interestingly, there was no signif-
icant decline in cognitive testing scores in the treatment groups
after treatment at the 6 month evaluation. However, when each
cognitive domain was analyzed, the treatment groups showed a
decline in attention capacity, learning memory and total mem-
ory. The authors did not comment on statistical signiﬁcance
of these results. In addition, the patients were only evaluated
6 months after therapy which may be too soon to properly assess
the impact of cancer treatment on cognition. It is also important
to note that all these studies are limited by their small sample
size.
BACKGROUND
The Geriatric Oncology clinic of the Segal Cancer Centre, Jewish
General Hospital, a McGill University teaching hospital in Mon-
treal, was founded in 2006 to address the unique needs of older
cancer patients. Patients are referred to our clinic for opinion
on cancer treatment plan, assessment of cognitive impairment
before, during or after cancer therapy, management of multi-
ple comorbidities, and functional decline. All patients undergo
a comprehensive geriatric assessment (CGA) which is comprised
of a multidimensional evaluation looking at health and func-
tional status, cognition, mood, nutrition, mobility, and frailty
markers. Speciﬁcally, our standard cognitive assessment includes
administering the mini-mental state examination (MMSE; Fol-
stein et al., 1975) and the Montreal Cognitive Assessment (MoCA;
Nasreddine et al., 2005). The purpose of using the MoCA is to
detect mild cognitive impairment in patients who score well on
the MMSE (i.e., a score> 26/30). Certain patients whose MMSE
and MoCA scores are inconclusive are referred for further eval-
uation by our Neuropsychologist. Finally, ancillary tests such
as routine blood tests [including thyroid-stimulating hormone
(TSH), Calcium level, vitamin B12, and folate levels] and brain
imaging [computed tomography (CT) scan, magnetic resonance
imaging (MRI), or positron emission tomography (PET) scan] are
performed to complete the work-up. Thus far, we have prospec-
tively gathered data from a total of 270 cancer patients. Of these,
212 patients were found to have cognitive impairment based on
an MMSE and/or MoCA score less than 26/30. The majority of
patients (68%) were female and the mean age was 79 years old
(SD = 8.1). The majority (68%) had no post-secondary edu-
cation. We further subdivided the patients into three diagnostic
categories: mild cognitive impairment n = 72 (27%), dementia
n = 54 (20%), possible/probable cancer and/or cancer therapy-
related cognitive impairment n= 44 (16%). Below,we present two
cases fromour clinicwhereby cancer treatmentmay have impacted
on the patient’s cognitive function. Of those whom we thought
may have cancer therapy-related cognitive impairment, we chose
to present patients who showed improvement on cognitive testing
after cessation of chemotherapy. These cases highlight the inherent
challenges in establishing a diagnosis of cancer therapy-related
cognitive impairment in older patients.
CASE 1
The ﬁrst case is a 75 year old male previously known only for
bilateral cataracts. He was diagnosed with stage III non-small cell
lung carcinoma at the age of 74 years following investigations for
a persistent cold. A routine X-ray revealed a right lower lobe lung
mass which was diagnosed as non-small cell lung cancer (NSCLC)
following aCT chest and bronchoscopy. He began gemcitabine but
experienced an adverse reaction and it was changed to carboplatin
and paclitaxel.
Previous to his cancer diagnosis and treatment, he lived in an
autonomous seniors’ residence with his wife. He was retired but
had previously worked as a laboratory technician and had a high
school level education. He was independent in all his activities of
daily living (ADLs) and most instrumental ADLs (IADLs) except
for cooking and shopping which were always carried out by his
wife. He ambulated independently. His wife noted that he was
becoming more forgetful in the 4 years prior to his cancer diag-
nosis. However, once initiating carboplatin/paclitaxel the patient
himself began complaining of forgetfulness and was referred to
our clinic by his pulmonary oncologist. Cognitive testing showed
a MMSE of 27/30 and a MoCA of 21/30 (normal score is ≥ 26).
He denied any depressive symptoms and scored 2/15 on the geri-
atric depression scale (GDS)which is negative for depression. ACT
headwas signiﬁcant only for an old lacunar infarct in the lentiform
nucleus. A PET scan did not reveal any metastatic disease.
A complete work-up was performed at the ﬁrst visit and all
blood tests were normal. A follow-up visit 5 months later while he
was still receiving chemotherapy revealed cognitive testing scores
of 30/30 on the MMSE and 23/30 on the MoCA test.
Two months after the cessation of the chemotherapy, the
patient’s cognitive testing scores improved, with a MMSE of 30/30
and a MoCA of 27/30). The patient also reported that, subjectively,
he found his memory to be improved.
It is important to note that the patient had a history of memory
problems predating the cancer diagnosis and treatment by 4 years.
In fact, it is possible that the patient may have been suffering from
baseline mild cognitive impairment. This may have put him at
higher risk of delirium secondary to chemotherapy. Furthermore,
the improvement of his cognitive testing scores could be explained
by a delirium which resolved given the relatively quick resolution
of his cognitive deﬁcits after cessation of chemotherapy.
CASE 2
The second case is a 65 year old female diagnosed with stage
I, estrogen receptor (ER)/progesterone receptor (PR) positive
breast cancer 3 years prior to our evaluation in the clinic.
She had undergone segmental mastectomy followed by adju-
vant cyclophosphamide, methotrexate and ﬂuorouracil (CMF)
chemotherapy, radiation therapy and was on exemestane at the
time of evaluation. She had been complaining of decreased mem-
ory and attention span since starting chemotherapy. The patient
underwent a CGA. She scored 30/30 on the MMSE and 21/30 on
the MoCA during her initial visit. Her depression screening test
was negative (GDS 3/15) and she denied depressive symptoms.
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Again, a routine work-up for common causes of her cognitive
impairment was negative (TSH, vitamin B12 level, CT head were
all normal). Neuropsychological testing revealed that her cognitive
proﬁle was mostly normal but that she did display attention and
concentration deﬁcits. In particular, she had deﬁcits in executive
functioning which indicated weak frontal lobe function and was
diagnosed with mild cognitive impairment.
The patient returned to clinic for an evaluation 1 year later. At
that time, she scored a 27/30 on the MoCA which was improved
from previous. The patient noted that her memory was better as
well. She was still on exemestane at the time of her second visit.
Again, these results illustrate how the exact mechanism for the
decline and subsequent improvement are difﬁcult to elucidate. Her
cognitive impairment was present years after her chemotherapy
and improved within 1 year of coming to our attention. Further-
more, the patient’s symptoms cannot be explained by her use of
hormone therapy as she improved while still using exemestane.
DISCUSSION
The evidence remains conﬂicting with regards to cancer
therapy-related cognitive dysfunction. Certain cross-sectional and
prospective studies have failed to prove its existence (Ruzich et al.,
2007; Du et al., 2010) while other prospective trials using in-
depth neuropsychiatric testing have shown that cancer therapy
does cause impairment in speciﬁc cognitive domains (Falleti et al.,
2005; Stewart et al., 2006, 2008; Quesnel et al., 2008; Jansen et al.,
2011). To explain these results, we turned to the literature and
belowwe present a brief summary of the research surrounding this
issue. It haswidely been accepted that patientswhohave been diag-
nosed with cancer may experience cognitive difﬁculties. Whether
this effect is due to cancer therapy, however, is still debated as con-
founding factors such as the cancer itself and its effect on mood
come into effect (Schilder et al., 2010).
Recent studies have suggested that the prevalence of cancer
therapy-related cognitive dysfunction ranges from 15 to 60%
(Ahles and Saykin, 2007); (Wefel et al., 2010). The lack of
pre-treatment screening makes it impossible to know to what
extent cognitive derangements can be attributed to therapy alone.
Furthermore, the lack of consensus on what kind of neuropsycho-
logical testing to use makes it difﬁcult to be able to corroborate
results of various studies.
Several prospective trials that have patients undergo neuropsy-
chological testing prior to chemotherapy have shown that there is
some degree of cognitive deﬁcits in a subset of cancer patients at
baseline that cannot be explained by psychiatric symptoms (Her-
melink et al., 2007; Hess et al., 2010; Jansen et al., 2011). Even
more interesting is that both Jansen et al. (2011) and Hermelink
et al. (2007) have shown that some cancer patients improve cog-
nitively after chemotherapy while others deteriorate. One study
aiming to explain this result looked at cancer patients treated
with and without chemotherapy and compared them with car-
diac patients and healthy controls (Mehlsen et al., 2009). Of note,
the healthy controls were participants recruited through the test
groups, colleagues, and students. In all, 34 cancer patients, 12
cardiac patients and 12 healthy controls were recruited. The age
of participants ranged from 18 to 65 years old. No signiﬁcant
change in neuropsychological testing between the three groupswas
observed at the various timepoints of testing. Itwas concluded that
chemotherapy does not confer an increased risk for cognitive dys-
function nor does it protect against it. Limits of this study include
the small sample size, the discrepancy in follow-up between the
cancer patients (6 months) and the controls (3 months) and the
wide age range which may skew the results of cognitive perfor-
mance. Immediate cognitive deﬁcits may have been missed as the
cancer patients were evaluated too long after chemotherapy.
While many studies have demonstrated a negative effect of
chemotherapy on cognition immediately after therapy, the long-
term effects remain to be seen. One study demonstrated that
breast cancer survivors over the age of 65 years who received
chemotherapy had evidence of neurocognitive deﬁcits 10 years
after chemotherapy compared to matched controls (Yamada
et al., 2010). These patients actually did signiﬁcantly worse on
dementia screening (MMSE 27.6 vs. 29.3 with p < 0.001). Fur-
thermore, the cancer survivors scored signiﬁcantly worse on
domains of attention, working memory, psychomotor speed, and
elements of executive functioning on neuropsychological test-
ing. Similarly, another study looked at cognitive function in
breast cancer survivors 20 years after their diagnosis (Koppel-
mans et al., 2012). In total, 196 patients who underwent CMF
chemotherapy during the years 1976–1995 were recruited. They
underwent neuropsychological testing and were compared to
controls who had never had cancer. This study was able to demon-
strate that, even 20 years after the completion of chemotherapy,
treated patients still performed worse on learning, verbal mem-
ory, information processing, inhibition, and psychomotor speed.
It is interesting to note that the chemotherapy group performed
no differently on dementia screening than did the random
controls.
Other studies in breast cancer patients have managed to show
some reversibility after the cessation of chemotherapy (Jansen
et al., 2011). One study actually observed that patients generally
did better on neuropsychological testing as time elapsed since the
time of their chemotherapy. However, 21% of the group still dis-
played deﬁcits on neuropsychological testing on average 9 months
post-treatment, chieﬂy in verbal-semantic memory (Weis et al.,
2009). Similarly, a study in 14 stage III NSCLC patients treated
with cisplatin/etoposide and radiotherapy showed similar results.
Of note, the investigators found that 71% of patients displayed
cognitive dysfunction prior to any treatment. Dysfunction per-
sisted 1 month after treatment but started to dissipate as early
as 7 months. The authors attribute this to the recovery from
neurotoxicity of chemotherapy (Whitney et al., 2008).
CONCLUSION
Cognitive dysfunction associated with cancer treatment, partic-
ularly chemotherapy and hormonal therapy, is a complex phe-
nomenon. Various studies show either inconclusive or, at times,
contradictory ﬁndings as it is difﬁcult to dissect the effect of cancer
itself, its effect on mood and energy and its treatment on cognitive
function. The assessment of cognitive function, especially before
cancer treatments, as proposed by both the SIOG (International
Society of Geriatric Oncology) and the senior adult oncol-
ogy guidelines of the NCCN (National Comprehensive Cancer
Network) is of particular importance in older cancer patients.
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Screening for cognitive deﬁcits at baseline provides valuable infor-
mation to determine patients’ ability to understand their cancer
diagnosis and proposed treatments as well as their decision-
making capacity. It may also impact on the decision of whether a
patient is a candidate for treatment.
As demonstrated in the ﬁrst case study, a diagnosis of cognitive
impairment at baseline confers a higher risk of delirium at any
time during a patient’s cancer care trajectory. Thus, recognizing
the possibility of delirium as a diagnosis and detecting problems
earlier can allow for preventative strategies to minimize the risk
of delirium. Another common problem in the elderly which can
impact on cognition is polypharmacy, often in the context of
multiple chronic diseases. Particular attention should be placed on
avoiding the use of inappropriate drugs in older adults (American
Geriatrics Society 2012 Beers Criteria Update Expert Panel, 2012)
and minimizing drug–drug and drug–disease interactions. Clini-
cians caring for the increasing number of older adults with cancer
should appreciate the importance and relevance of cognitive func-
tion in that population. Moreover, the potential deleterious impact
of cancer therapy on cognition adds another level of complexity
which should be acknowledged and addressed. Further research
in this ﬁeld is needed and the advent of more prospective studies
conducted over a longer time periodwill hopefully shedmore light
on this pertinent topic.
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